The FY23 MRP Idea Award supports innovative, untested, exploratory, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods that address at least one of the FY23 MRP Focus Areas in Section II.A.

1. Key aspects of the Idea Award:The intent of the Idea Award is to generate

credit: Run Luau Run

How's Your Community Doing?
Check Out it's
Community Vital Signs

novel research avenues for investigation; therefore, novelty and innovation should be key aspects of the proposed research.

Research supported by the Idea Award must introduce a new paradigm, challenge existing paradigms, look at existing problems from new perspectives, or exhibit other highly creative qualities.

The proposed project can be exploratory, hypothesis-driven, or hypothesis-generating research but must be based on a strong scientific rationale and a well-developed study design and plan of analysis.The Idea Award is not intended to expand or extend previously published findings or continue a line of research already established in the applicant’s laboratory.

Incremental advances, the next logical step, or merely switching the object or method of inquiry from one cancer to another cancer is not considered innovative.

The expected outcome of research supported by this award is the generation of robust preliminary data to be used as a foundation for future melanoma-focused research projects.Inclusion of preliminary data is discouraged.

Principal Investigators (PIs) proposing projects already supported by significant preliminary data should consider applying to other FY23 MRP funding opportunities for which the inclusion of preliminary data is more appropriate or required.

Inclusion of preliminary data other than serendipitous findings is not consistent with the exploratory/innovative nature of this award.

If preliminary data are included, they should be unanticipated outcomes or results from an unrelated project or study.